ストックスクリーナーアプリを入手
1.76
2.22%
-0.04
前日終値:
$1.80
開ける：
$1.82
24時間の取引高:
9,529
Relative Volume:
0.71
時価総額：
$12.59M
収益：
-
当期純損益:
$-33.65M
株価収益率:
-0.3955
EPS:
-4.45
ネットキャッシュフロー:
$-20.83M
1週間 パフォーマンス:
-0.56%
1か月 パフォーマンス:
+18.12%
6か月 パフォーマンス:
-22.12%
1年 パフォーマンス:
-42.30%
1日の値動き範囲:
$1.75
$1.82
1週間の範囲:
$1.75
$1.8812
52週間の値動き範囲:
$1.15
$3.499
Minerva Neurosciences Inc Stock (NERV) Company Profile
名前
Minerva Neurosciences Inc
セクター
電話
617-600-7373
住所
1601 TRAPELO ROAD, WALTHAM, MA
NERV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
1.76 | 12.59M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.64 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
524.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.86 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
561.79 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.93 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-14 | 開始されました | BTIG Research | Buy |
| 2019-10-02 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-09-25 | 開始されました | Chardan Capital Markets | Buy |
| 2019-09-18 | 開始されました | William Blair | Outperform |
| 2019-05-31 | 開始されました | H.C. Wainwright | Buy |
| 2017-09-01 | 開始されました | Citigroup | Buy |
| 2017-03-06 | 再開されました | Jefferies | Buy |
| 2016-05-12 | 再開されました | Jefferies | Buy |
すべてを表示
Minerva Neurosciences Inc (NERV) 最新ニュース
Citadel Advisors LLC Makes New Investment in Kuke Music Holding Limited (NYSE:KUKE) - Defense World
Citadel Advisors LLC Purchases New Holdings in Jiuzi Holdings, Inc. (NASDAQ:JZXN) - Defense World
Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares Bought by Citadel Advisors LLC - Defense World
Minerva Neurosciences Reports Q1 2025 Earnings and Regulatory Challenges - TipRanks
Major Depressive Disorder Pipeline Appears Robust With 75+ Key Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares Bought by Northern Trust Corp - Defense World
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at Wall Street Zen - Defense World
Minerva Neurosciences: Q1 Earnings Snapshot - CT Insider
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
NERV's Cash Reserves Decrease by $4.1 Million in Q1 2025 | NERV Stock News - GuruFocus
Minerva Neurosciences Reports First Quarter 2025 Financial Resul - GuruFocus
MINERVA NEUROSCIENCES Earnings Results: $NERV Reports Quarterly Earnings - Nasdaq
Minerva Neurosciences, Inc. SEC 10-Q Report - TradingView
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com - Defense World
Minerva Neurosciences (NERV) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Renaissance Technologies LLC Has $285,000 Stock Holdings in Minerva Neurosciences, Inc. (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World
Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.
Schizophrenia Market to Witness Significant Growth by 2034 - GlobeNewswire
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - The AM Reporter
CLASS ACTION UPDATE for TILE, NERV and QSR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
CLASS ACTION UPDATE for BABA, NAK and NERV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
Minerva Neurosciences stock hits 52-week low at $1.29 - Investing.com Australia
Minerva Neurosciences stock hits 52-week low at $1.29 By Investing.com - Investing.com South Africa
Major depressive disorder Drugs Market 2034: Clinical Trials, - openPR.com
Minerva Neurosciences regains Nasdaq compliance By Investing.com - Investing.com Australia
Minerva Neurosciences regains Nasdaq compliance - Investing.com India
FINAL DEADLINE ALERT: ROSEN, LEADING AND RESPECTED INVESTOR COUNSEL, Encourages Minerva Neurosciences, Inc. Investors with Large Losses to Secure Counsel Before Important February 8 Deadline – NERV - Business Wire
Parkinson's Disease Clinical Pipeline | 130+ Companies Advancing the Future of Treatment - openPR
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld MedTech
Minerva Neurosciences Reports Improved 2024 Financials - TipRanks
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Minerva Neurosciences Inc (NERV) 財務データ
収益
当期純利益
現金流量
EPS
1.37%
0.65%
大文字化:
|
ボリューム (24 時間):